Adenosine Baxter

देश: न्यूज़ीलैंड

भाषा: अंग्रेज़ी

स्रोत: Medsafe (Medicines Safety Authority)

सक्रिय संघटक:

Adenosine 3 mg/mL;  ;  

थमां उपलब्ध:

Baxter Healthcare Ltd

INN (इंटरनेशनल नाम):

Adenosine 3 mg/mL

डोज़:

30 mg/10mL

फार्मास्यूटिकल फॉर्म:

Solution for infusion

रचना:

Active: Adenosine 3 mg/mL     Excipient: Sodium chloride Water for injection

प्रिस्क्रिप्शन प्रकार:

Prescription

द्वारा बनाया गया:

Xinxiang Tuoxin Biochemical Technology & Science Co Ltd

चिकित्सीय संकेत:

Intravenous Adenosine Baxter 30 mg/10 ml is a coronary vasodilator for use in conjunction with radionuclide myocardial perfusion imaging, in patients unable to exercise adequately.

उत्पाद समीक्षा:

Package - Contents - Shelf Life: Vial, glass, sulfur-treated Ph Eur type I clear 10 mL with teflon-coated rubber stopper - 5 dose units - 24 months from date of manufacture stored at or below 30°C. Do not refrigerate - Vial, glass, sulfur-treated Ph Eur type I clear 10 mL with teflon-coated rubber stopper - 10 dose units - 24 months from date of manufacture stored at or below 30°C. Do not refrigerate

प्राधिकरण की तारीख:

2016-12-19

उत्पाद विशेषताएं

NEW ZEALAND DATA SHEET
ADENOSINE BAXTER Data Sheet 11 January 2024
Page 1 of 9
Baxter Healthcare Ltd
1 PRODUCT NAME
ADENOSINE BAXTER 30mg/10mL solution for infusion.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
_ACTIVE INGREDIENT _
ADENOSINE BAXTER solution for infusion vials contain 30mg in 10mL
adenosine (equivalent to 3mg/mL).
For the full list of excipients see section 6.1.
3 PHARMACEUTICAL FORM
Solution for infusion.
Clear, colourless to almost colourless solution essentially free from
visible particles.
4 CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Intravenous ADENOSINE BAXTER 30mg/10mL is a coronary vasodilator for
use in conjunction with
radionuclide myocardial perfusion imaging, in patients unable to
exercise adequately.
4.2
DOSE AND METHOD OF ADMINISTRATION
ADENOSINE BAXTER 30mg/10mL is intended for use in hospitals, where
facilities for cardiac monitoring and
resuscitation are available.
_DIAGNOSTIC DOSE_
_Adults_
1.
ADENOSINE BAXTER 30mg/10mL should be administered undiluted as a
continuous peripheral
intravenous infusion at a dose of 140µg/kg/min over fixed time
interval of six minutes (total dose
0.84mg/kg) using an infusion pump. Separate venous sites for ADENOSINE
BAXTER 30mg/10mL and
radionuclide administration are recommended to avoid an adenosine
bolus effect.
2.
After three minutes of ADENOSINE BAXTER 30mg/10mL infusion, the
radionuclide is injected.
3.
Heart rate and blood pressure should be recorded at 1-minute
intervals, and ECG should be monitored
continuously during ADENOSINE BAXTER 30mg/10mL infusion. To avoid an
adenosine bolus effect, blood
pressure should be measured in the arm opposite to the ADENOSINE
BAXTER 30mg/10mL infusion.
The table below is given as a guide for adjustment of the infusion
rate of undiluted ADENOSINE BAXTER
30mg/10mL, in line with body weight (total dose 0.84mg/kg).
PATIENT WEIGHT (KG)
INFUSION RATE (ML/MIN)
45‐49
2.1
50‐54
2.3
55‐59
2.6
60‐64
2.8
65‐69
3.0
70‐74
3.3
75‐79
3.5
80‐84
3.8
85‐89
4.0
90‐94
4.2
95‐99
4.4
100‐104
4.7
_Child